8-K: Senseonics Reports Fourth Quarter and Full Year 2024 Financial Results, Highlights Eversense 365 Approval and Launch

Senseonics Holdings, Inc. announced its Q4 and full year 2024 financial results, highlighting FDA approval and launch of Eversense 365, a 56% increase in patient base, and a positive outlook for 2025.

Summary

• Senseonics Holdings, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company received FDA approval for the Eversense 365 Continuous Glucose Monitoring (CGM) system and launched it with commercial partner Ascensia.
• The patient base increased by 56% in 2024 compared to 2023, reaching approximately 6,000 global patients.
• Fourth quarter revenue was $8.3 million, compared to $8.0 million in the fourth quarter of 2023.
• Full year 2024 revenue was $22.5 million, slightly up from $22.4 million in 2023.
• The company executed a restructuring process targeting a $10 million reduction in cash operating expenses in 2025.
• Senseonics raised gross proceeds of over $20 million in 2024 and approximately $27.0 million in early 2025 through equity offerings.
• The company expects full-year 2025 global net revenue to be approximately $34-38 million.
• Gross margins are expected to increase throughout 2025, with full year gross margins between 25-30%.
• Cash utilization in 2025 is expected to be between $50-$60 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company has achieved key milestones with the FDA approval and launch of Eversense 365, and patient growth is strong. However, the company is still loss making and faces significant competition. The revenue guidance for 2025 is encouraging, but execution is key.

Positives

• FDA approval and launch of Eversense 365 is a major milestone.
• Significant increase in patient base demonstrates growing adoption.
• Strong new patient shipments in December indicate positive market reception.
• High percentage of patients switching from competitors suggests a competitive advantage.
• Restructuring efforts are expected to reduce operating expenses.
• Successful equity offerings have strengthened the balance sheet.
• Revenue is expected to grow significantly in 2025.
• Gross margins are projected to improve substantially in 2025.

Negatives

• Full year 2024 gross profit decreased from $3.1 million in 2023 to $0.5 million, primarily driven by one-time charges related to the transition from Eversense E3 to Eversense 365.
• Net loss increased by $18.2 million in 2024 compared to 2023, primarily due to a reduction in gains from convertible notes and changes in the fair value of derivatives.
• Selling, general and administrative expenses increased by $4.3 million year-over-year in 2024.
• Cash utilization in 2025 is expected to be between $50-$60 million.

Risks

• The company's success is heavily reliant on its commercial partnership with Ascensia Diabetes Care.
• Uncertainties exist in insurer, regulatory, and administrative processes.
• The development and rollout of new technology and solutions carry inherent risks.
• The company faces uncertainties related to the economic and regulatory/political environment.
• The company's forward looking statements are subject to risks and uncertainties.

Future Outlook

Senseonics anticipates full-year 2025 global net revenue to be approximately $34-38 million, with gross margins between 25-30%. Cash utilization in 2025 is expected to be between $50-$60 million. The company expects to approximately double its global patient base in 2025.

Management Comments

• Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics, stated that Eversense 365 is the catalyst for revenue growth and the future of blood glucose monitoring.
• Brian Hansen, President of CGM at Ascensia Diabetes Care, noted positive key commercial metrics for Eversense in the early months of the U.S. launch.

Industry Context

The announcement reflects the ongoing competition in the continuous glucose monitoring market, with Senseonics aiming to differentiate itself through its long-term implantable technology. The collaboration with Ascensia is crucial for commercial success, and the focus on remote patient monitoring aligns with broader trends in healthcare.

Comparison to Industry Standards

• Dexcom and Abbott are the market leaders in the CGM space.
• Dexcom reported revenue of $3.66 billion in 2023, while Abbott's diabetes care sales were $5.7 billion.
• Senseonics' 2024 revenue of $22.5 million is significantly smaller, indicating a much smaller market share.
• The 56% patient growth is a positive sign, but the company needs to continue to scale to compete effectively.
• The Eversense 365's 365-day sensor life is a key differentiator compared to Dexcom's and Abbott's shorter-duration sensors.

Stakeholder Impact

• Shareholders: The financial results and future outlook will impact shareholder value.
• Patients: The availability of Eversense 365 provides a new option for diabetes management.
• Employees: The restructuring process may impact employees.
• Ascensia: The partnership with Ascensia is critical for commercial success.

Next Steps

• Continue commercial rollout of Eversense 365 in the U.S.
• Pursue CE Mark approval and launch in the European Union.
• Advance development programs for next-generation Gemini and Freedom systems.
• Add automated insulin delivery with pump connectivity to Eversense 365.
• Execute restructuring plan to reduce operating expenses.

Key Dates

Keywords

Senseonics, Eversense 365, Continuous Glucose Monitoring, CGM, Financial Results, Diabetes, Ascensia, Revenue, Patient Base, FDA Approval